Syngenta AG to Invest in New U.S. Genetics Research Facility

BASEL, Switzerland, May 20, 2011 /PRNewswire/ -- Syngenta announced today that it plans to construct a new state-of-the-art biotechnology research facility adjacent to its existing research campus in Research Triangle Park, North Carolina. The $71 million investment, which is scheduled to begin in June 2011, will focus on discovering and developing new agronomic traits to bring innovative solutions to growers across the world.

"This investment demonstrates our commitment to R&D and to remain at the forefront of plant genetics research," said Sandro Aruffo, Syngenta Head of Research and Development. "The advanced technologies that will be implemented at this new site will accelerate our R&D efforts to develop agronomic traits that will enable crops to better withstand complex environmental challenges."

Building on the recent successful launches of Agrisure Viptera, Agrisure Artesian and Enogen, research at the site will focus on traits that can better tolerate climate variability, combat plant stresses such as drought, and enhance crop productivity and plant performance. In addition to the current focus on corn and soybean, research will be expanded to incorporate other crops such as sugar cane, cereals, rice and vegetables.

The facility will feature research laboratories and sophisticated growth environments including climate-controlled greenhouses and precision growth chambers. It is expected to be fully operational in the second half of 2012.

Syngenta is one of the world's leading companies with more than 26,000 employees in over 90 countries dedicated to our purpose: Bringing plant potential to life. Through world-class science, global reach and commitment to our customers we help to increase crop productivity, protect the environment and improve health and quality of life. For more information about us please go to www.syngenta.com

Cautionary Statement Regarding Forward-Looking Statements

This document contains forward-looking statements, which can be identified by terminology such as 'expect', 'would', 'will', 'potential', 'plans', 'prospects', 'estimated', 'aiming', 'on track' and similar expressions. Such statements may be subject to risks and uncertainties that could cause the actual results to differ materially from these statements. We refer you to Syngenta's publicly available filings with the U.S. Securities and Exchange Commission for information about these and other risks and uncertainties. Syngenta assumes no obligation to update forward-looking statements to reflect actual results, changed assumptions or other factors. This document does not constitute, or form part of, any offer or invitation to sell or issue, or any solicitation of any offer, to purchase or subscribe for any ordinary shares in Syngenta AG, or Syngenta ADSs, nor shall it form the basis of, or be relied on in connection with, any contract therefor.

Syngenta International AG


Media Office

CH-4002 Basel

Switzerland

Tel: +41 61 323 23 23

Fax: +41 61 323 24 24


www.syngenta.com

Media contacts:


Michael Edmond Isaac

Switzerland +41 61 323 2323


Paul Minehart

USA +1 202 737 8913


Analyst/Investor contacts:


Jennifer Gough

Switzerland +41 61 323 5059

USA +1 202 737 6521


Claire Hinshelwood

Switzerland +41 61 323 7812

USA +1 202 737 6520



SOURCE Syngenta

Back to news